LungLife AI Inc (LLAI) USD0.0001 (DI)
No change
- Add to watchlist
- Create an alert
- This stock can be held in a
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
No change
Deal for just £11.95 per trade in a
Stocks and Shares ISA,
Lifetime ISA
,
SIPP
or
Fund and Share Account
Business summary
LungLife AI, Inc. is a developer of clinical diagnostic solutions for lung cancer. The Company is engaged in the development and commercialization of its lung cancer early detection test. Using a minimally invasive blood draw, its LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. LungLB is a blood-based liquid biopsy assay that uses fluorescence in situ hybridization (FISH) and image analysis to identify circulating genetically abnormal cells (CGAC), which include circulating tumor cells (CTCs). The technique incorporates an artificial intelligence (AI)-derived image analysis strategy to identify unique cell populations reflective of the disease state under interrogation.
Contact details
Important dates
General stock information
- EPIC:
- LLAI
- ISIN:
- USU5500L1045
- Market cap:
- £3.53 million
- Shares in issue:
- 30.66 million
- Sector:
- No specific Industry
- Exchange:
- London Stock Exchange
- Currency:
- Sterling pence
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.